However, KRAS G12C-mutant selective irreversible inhibitors, such as sotorasib and adagrasib, have demonstrated meaningful clinical activity in heavily pre-treated patients with metastatic KRAS G12C-mutated PDAC and CRC [24,25]. Here, KRAS is linked to colorectal carcinoma.